Shares of USA-based tumor drug resistance specialist Deciphera Pharmaceuticals (Nasdaq: DCPH) soared 73% to $25.34 in morning trading, on the news that it has received a takeover bid.
Decipher revealed it has entered into a definitive merger agreement with Ono Pharmaceutical (TYO: 4528) under which the Japanese drugmaker will acquire all outstanding shares of Deciphera common stock through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO.
Ono will acquire all outstanding shares of Deciphera for $25.60 per share in cash for a total equity value of approximately $2.4 billion. The purchase price represents a premium of 74.7% to Deciphera’s closing share price of $14.65 on April 26, 2024, and a premium of 68.8% to Deciphera’s 30-trading-day volume weighted average price as of April 26. The deal is expected to close in the third quarter of 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze